IN THE CLAIMS

The following claim set replaces all prior versions, and listings, of claims in the application:

Claims 1-19 (cancelled).

20. (previously added) A kit of parts comprising:

(a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and

(b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,

which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

21. (previously added) A kit of parts as claimed in Claim 20, wherein the prodrug of component (b) is a prodrug of the thrombin inhibitor of component (a).

22. (previously added) A kit of parts as claimed in Claim 20, wherein components (a) and (b) are suitable for sequential, separate or simultaneous use in the treatment of a condition in which inhibition of thrombin is required or desired.

23. (previously added) A kit of parts as claimed in Claim 22, wherein the

condition is deep venous thrombosis.

24. (previously added) A kit of parts as claimed in Claim 20, wherein the thrombin inhibitor is melagatran.

B1

25. (currently amended) A kit of parts as claimed in Claim ~~26~~24, wherein the prodrug is of the formula

$R^1O_2C\text{-}CH_2\text{-}(R)Cgl\text{-}Aze\text{-}Pab\text{-}OH$,

wherein R^1 represents linear or branched $C_{1\text{-}6}$ alkyl and the OH group replaces one of the amidino hydrogens in Pab.

26. (previously added) A kit of parts as claimed in Claim 25, wherein R^1 represents methyl, ethyl or propyl.

27. (previously added) A kit of parts as claimed in Claim 25, wherein R^1 represents ethyl.

28. (previously added) A kit of parts as claimed in Claim 20, 21, 24 or 27, wherein the formulation comprising thrombin inhibitor, or derivative thereof, is a parenteral formulation and that comprising the prodrug, or derivative thereof, is an oral formulation.

29. (previously added) A method of making a kit of parts as defined in Claim 20, 21, 24 or 27, which method comprises bringing a component (a) into association with a component (b), thus rendering the two components suitable for administration in conjunction with each other.

30. (previously added) A kit of parts comprising:

(1) one of components (a) and (b) as defined in Claim 20, 21, 24 or 27;

together with

(2) instructions to use that component in conjunction with the other of the two components.

31. (previously added) A pharmaceutical formulation including a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative thereof) and a prodrug of a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative of that prodrug), in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

B2

32. (currently amended) A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of:

(a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction

with

(b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,

to a patient suffering from, or susceptible to, such a condition for a time and under conditions suitable for reducing the incidence of said condition.

33. (previously added) A method as claimed in Claim 32 in which component (a) is administered prior to commencement of administration of component (b).

34. (currently amended) A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of a formulation as defined in Claim 31 to a patient suffering from, or susceptible to, such a condition for a time and under conditions suitable for reducing the incidence of said condition.

35. (previously added) A method as claimed in Claim 32, wherein the condition is deep venous thrombosis.

36. (previously added) A method as claimed in Claim 35, wherein the thrombosis results from surgery.

37. (previously added) A method as claimed in Claim 36, wherein the surgery is gastrointestinal surgery or orthopedic surgery.

38. (previously added) A method as claimed in Claim 36, wherein component (a) is administered parenterally prior to or after surgery and component (b) is administered orally following that surgery.

39. (previously added) A method as claimed in Claim 36, wherein component (a) is administered parenterally prior to and after surgery and component (b) is administered orally following that surgery.

40. (previously added) A method as claimed in Claim 32, 35, 36, 37, 38 or 39, wherein the thrombin inhibitor is melagatran.

B4

41. (currently amended) A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of:

(a) a pharmaceutical formulation including melagatran, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction with

(b) a pharmaceutical formulation including a prodrug of formula

R^1O_2C-CH_2-(*R*)Cgl-Aze-Pab-OH,

wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,

to a patient suffering from, or susceptible to, such a condition for a time and under conditions suitable for reducing the incidence of said condition.

B4 Conclude

42. (currently amended) A method ~~according to~~ as claimed in Claim 41, wherein R^1 represents methyl, ethyl or propyl.

43. (currently amended) A method ~~according to~~ as claimed in Claim 41, wherein R^1 represents ethyl.

B5

44. (new) A method as claimed in Claim 32 wherein the prodrug of component (b) is a prodrug of the thrombin inhibitor of component (a).

45. (new) A pharmaceutical formulation as claimed in Claim 31 wherein the prodrug is a prodrug of the thrombin inhibitor.

46. (new) A pharmaceutical formulation as claimed in Claim 31 wherein the thrombin inhibitor is melagatran.

47. (new) A pharmaceutical formulation as claimed in Claim 46 wherein the prodrug is of the formula

R^1O_2C-CH_2-(*R*)Cgl-Aze-Pab-OH,

wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amidino hydrogens in Pab.

48. (new) A pharmaceutical formulation as claimed in Claim 47 wherein R^1 represents methyl, ethyl, or propyl.

49. (new) A pharmaceutical formulation as claimed in Claim 47 wherein R^1 represents ethyl.

B3 cont.

50. (new) A method as claimed in claimed 34 wherein the prodrug is a prodrug of the thrombin inhibitor.

51. (new) A method as claimed in Claim 34 wherein the condition is deep venous thrombosis.

52. (new) A method as claimed in Claim 51 wherein the thrombosis results from surgery.

53. (new) A method as claimed in Claim 52 wherein the surgery is gastrointestinal surgery or orthopedic surgery.

54. (new) A method as claimed in Claim 34 wherein the thrombin inhibitor is melagatran.

55. (new) A method according to Claim 34 wherein the thrombin inhibitor is melagatran, and the prodrug is of formula

R^1O_2C-CH_2-(*R*)Cgl-Aze-Pab-OH,

wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amdino hydrogens in Pab.

BS conclude

56. (new) A method as claimed in Claim 55, wherein R^1 represents methyl, ethyl or propyl.

57. (new) A method as claimed in Claim 55, wherein R^1 represents ethyl.